Is Your Child a Good Candidate for a Groundbreaking Leukemia Treatment?
Gene therapy recently approved by the FDA for certain young leukemia patients is a first in the U.S. The treatment modifies a patient’s own immune cells to fight the leukemia.
You may have hear about the recent approval by the Food and Drug Administration (FDA) of the first gene therapy treatment in the United States. It’s now available to treat some pediatric patients with acute lymphoblastic leukemia (ALL).
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
ALL is a blood and bone marrow cancer in children. It causes immature white blood cells to grow out of control. This condition progresses quickly and can be fatal within months if left untreated.
ALL is the most common childhood cancer in the United States, and affects up to 5,000 children each year.
The new treatment, called tisagenlecleucel and sold under the brand name Kymriah™, can treat patients up to age 25 who have not responded to initial chemotherapy or who have had a relapse after treatment. This occurs in up to 20 percent of those with ALL. Until now, there have been few treatment options for these patients.
The FDA approval applies to a fairly small group of patients. But oncologists view it as an important beginning.
“This therapy is truly remarkable,” says Mikkael Sekeres, MD, Director of the Leukemia Program at Cleveland Clinic Cancer Center. “This is a vanguard of cancer therapy that we’re going to see more and more of in the future.”
Kymriah™ is an immunotherapy treatment that focuses on patients whose ALL affects B-cells, a type of white blood cell.
The therapy works by genetically modifying immune cells collected from a patient’s blood, adding a gene with a protein called chimeric antigen receptor (CAR).
The treatment team then returns the modified blood to the patient to do its job of finding and destroying leukemia cells..
“This is a paradigm shift, a real step forward in personalized treatments for cancer,” Dr. Sekeres says. Physicians, he says, “are very hopeful that this is just the beginning.”
The treatment’s clinical trial was a small one, with only 63 pediatric patients. But the results were impressive: Within three months of treatment, patients had an overall remission rate of 83 percent, Dr. Sekeres says.
The follow-up on patients was short — only about five months after treatment. The drugmaker, Novartis, is continuing with a long-term observational study of the participants. Doctors consider ALL cured when patients are free of the condition for four years after treatment ends.
Though Kymriah™ appears to be highly effective, it comes with potential serious side effects, Dr. Sekeres says.
It can cause a condition called cytokine release syndrome (CRS), which produces high fever and flu-like symptoms. CRS is sometimes life-threatening.
In response, the FDA has expanded the use of tocilizumab, which is sold under the brand name Actemra® to treat CRS in children ages 2 and older. Studies show that Actemra® can eliminate CRS within two weeks for many patients.
Kymriah™ can also cause potentially life-threatening neurological problems. More minor side effects, which may occur within a month of treatment, include:
Gene therapy like Kymriah™, which uses a person’s own cells to fight cancer, is a new and promising approach to ALL, Dr. Sekeres says. It holds promise for many other challenging health conditions as well. Your child’s pediatrician can help you determine whether he or she is a candidate for the therapy.